Skip to main navigation Investors & Media NYSE: ZYME Price $18.70 Change -1.235 (-6.19%) Volume 1,048,955 As of Nov 23, 2021 3:30 PM EST Data Provided by Refinitiv. Minimum 15 minutes delayed. MENU INVESTOR RELATIONS Latest News & Media We are committed to providing the public equal access to information. VIEW ARTICLES Corporate Presentation Understand Zymeworks and how the Company is growing into a major biotech corporation. VIEW PRESENTATION Events/Webcast Evercore ISI 4th Annual HEALTHCONx Virtual Conference 11/30/2021 at 3:05 PM EST COMPANY PROFILE Zymeworks Inc. is a publicly listed (NYSE: ZYME), clinical-stage, biopharmaceutical company dedicated to the discovery, development, and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer. Zymeworks’ suite of complementary therapeutic platforms and its fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated product candidates. Zymeworks’ lead product candidate, Zanidatamab, is a HER2-targeted bispecific antibody developed using Zymeworks proprietary Azymetric™ platform. Zanidatamab is currently being evaluated in global Phase 1, Phase 2, and Registration-Enabling clinical trials as a best-in-class treatment for patients with HER2-expressing cancers, including biliary tract, gastroesophageal adenocarcinomas, breast, and other tumor types. Zymeworks’ second candidate, ZW49, is a HER2-targeted antibody drug conjugate (ADC) developed using Zymeworks’ proprietary Azymetric™ and ZymeLink™ platforms. ZW49 is currently being evaluated in a Phase 1 clinical trial as a treatment for patients with HER2-expressing cancers. Zymeworks is also advancing a deep pipeline of preclinical product candidates and discovery-stage programs in oncology (including immuno-oncology agents) and other therapeutic areas. In addition to Zymeworks’ wholly owned pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. Latest 10-K Latest 10-Q Latest Proxy PRESS RELEASES Zymeworks Announces Abstract for Zanidatamab in Late-Line HER2-Positive Breast Cancer at the San Antonio Breast Cancer Symposium (SABCS) 11/19/2021 Zymeworks Names Neil Josephson, M.D., Chief Medical Officer 11/9/2021 Zymeworks Launches Global Phase 3 Zanidatamab Trial in First-Line HER2‑Positive Gastroesophageal Adenocarcinoma (GEA) 11/9/2021 SEE ALL PRESS RELEASES EMAIL ALERTS Sign up to receive email alerts of our latest events & webcasts, financial reports, SEC filings and more. SUBSCRIBE Copyright 2021 , Zymeworks Inc. CLIENT FOOTER LINKS TECHNOLOGY Azymetric™ ZymeLink™ EFECT™ Science PIPELINE Zanidatamab ZW49 Preclinical Candidates Partnerships Publications For Patients INVESTORS Stock Info Press Releases Events & Presentations Financials Governance CORPORATE Leadership Board of Directors Careers Legal Privacy Contact Twitter LinkedIn